[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Wangjing Hospital, China Academy of Chinese Medical Sciences\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":143},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,63,90,119],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":62},"100643232","a-multicenter-registry-based-study-across-the-spectrum-of-degenerative-cervical-myelopathy-100643232",false,"NCT07641699","A Multicenter Registry-Based Study Across the Spectrum of Degenerative Cervical Myelopathy","A Multicenter Registry-Based Study of Degenerative Cervical Myelopathy Across the Full Disease Spectrum Based on a Disease-Specific Registry Platform and Linked Biobank","DCM-RB","Inclusion Criteria:\n\n* Age 18 years or older.\n* Cervical MRI confirms cervical spinal cord compression caused by degenerative pathology, including but not limited to disc protrusion or bulging, osteophyte formation, ligamentum flavum hypertrophy or ossification, ossification of the posterior longitudinal ligament, degenerative cervical canal stenosis, or other degenerative compressive factors.\n* At least one cervical level meets one or more of the following imaging criteria: partial or complete disappearance of the cerebrospinal fluid space around the spinal cord, direct contact between the spinal cord and degenerative compressive structures, focal spinal cord indentation, flattening or deformation, or other recognized imaging manifestations of degenerative cervical cord compression.\n* Meets one of the following clinical phenotypes: non-myelopathic degenerative cervical cord compression, with or without clinical radiculopathy; or clinically and radiologically confirmed mild, moderate, or severe degenerative cervical myelopathy.\n* Able to complete baseline core assessments and willing to participate in longitudinal follow-up.\n* Provides written informed consent. Additional consent may be obtained for specific biospecimen types or nested substudies.\n\nExclusion Criteria:\n\n* Cervical spinal cord compression or myelopathy mainly caused by non-degenerative etiologies, such as acute trauma, tumor, infection, inflammatory or demyelinating disease, vascular lesion, obvious congenital malformation, or other non-degenerative spinal cord disease.\n* Presence of a dominant other neurological disease or severe psychiatric or cognitive disorder that, in the investigator's judgment, would clearly interfere with DCM-related neurological functional assessment or make reliable follow-up impossible.\n* Objective inability to complete the core imaging assessment or core follow-up and judged by the investigator to be unsuitable for inclusion in the main registry cohort.\n* Refusal to sign informed consent or explicit refusal of core data collection and follow-up.",true,"ALL","18 Years",{"count":21,"type":22},200,"ESTIMATED","36 Months","OBSERVATIONAL","This is a multicenter, prospective, longitudinal, observational registry-based study of degenerative cervical myelopathy (DCM) across the full disease spectrum, linked to a disease-specific biobank. The study will enroll adults with non-myelopathic degenerative cervical cord compression, including asymptomatic degenerative cervical cord compression with or without radiculopathy, as well as patients with mild, moderate, or severe DCM. The study does not assign treatment or interfere with real-world clinical decision-making. All participants will undergo standardized baseline assessment, scheduled follow-up, and event-driven supplemental data collection. Core data include demographic information, comorbidities, disease characteristics, neurological examination, objective functional tests, patient-reported outcomes, cervical MRI findings, treatment pathway, treatment changes, adverse events, and long-term clinical outcomes. In participating centers, standardized biospecimen collection will be performed to support nested biomarker, immune, imaging, electrophysiological, and traditional Chinese medicine syndrome substudies. The main objective is to establish a standardized multicenter registry platform covering non-myelopathic degenerative cervical cord compression and mild, moderate, and severe DCM; to describe clinical trajectories, imaging evolution, treatment pathways, and long-term outcomes; and to identify factors associated with disease deterioration and functional prognosis.",[27,28,29,30],"Degenerative Cervical Myelopathy","Non-myelopathic Degenerative Cervical Cord Compression","Asymptomatic Degenerative Cervical Cord Compression","Cervical Spinal Cord Compression",[32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49],"Degenerative cervical myelopathy","DCM","Non-myelopathic degenerative cervical cord compression","NMDCCC","Asymptomatic degenerative cervical cord compression","ADCC","Cervical spinal cord compression","Cervical spondylotic myelopathy","Patient registry","Biobank","Natural history","Disease progression","mJOA","Cervical MRI","Diffusion tensor imaging","T2 mapping","Blood biomarker","Traditional Chinese medicine syndrome","NOT_YET_RECRUITING","2026-06-07",{"date":53,"type":54},"2026-06-11","ACTUAL",{"date":56,"type":22},"2026-06-01",{"date":58,"type":22},"2031-12-31",{"name":60,"class":61},"Wangjing Hospital, China Academy of Chinese Medical Sciences","OTHER",1,{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":17,"sex":18,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":73,"conditions":74,"keywords":77,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":5},"100617682","osteoporotic-vertebral-compression-fracture-cohort-study-100617682","NCT07321795","Osteoporotic Vertebral Compression Fracture Cohort Study","Osteoporotic Vertebral Compression Fractures: A Multi-center Cohort Study Based on Disease and Syndrome Differentiation","Inclusion Criteria:\n\n1.50 years ≤ age \\\u003C 80 years; gender includes both male and female. 2.Meet the diagnostic criteria for new-onset osteoporotic vertebral compression fracture.\n\n3.Voluntarily participate in this clinical study and sign the informed consent form.\n\nSubjects meeting only criteria (1) and (3) with a T-score ≥ -1.0 can be included in the normal bone mass group. Subjects meeting criteria (1) and (3) with -2.5 \\\u003C T-score \\\u003C -1.0 can be included in the osteopenia group. Subjects meeting criteria (1) and (3) with T-score ≤ -2.5, meeting the diagnostic criteria for osteoporosis, can be included in the OP group. Subjects meeting all criteria (1), (2), and (3) will be included in the OVCF patient group.\n\nExclusion Criteria:\n\n1. Patients with serious concomitant cardiovascular\u002Fcerebrovascular diseases, liver\u002Fkidney diseases, malignant tumors, or other wasting diseases, and patients with infectious diseases.\n2. Patients with other endocrine system diseases, such as Cushing's syndrome, hyperthyroidism, hypothyroidism, etc.\n3. Patients who have participated in other clinical trials within the past 3 months.\n4. Patients with concomitant Alzheimer's disease, mental illnesses or depression, or those unable to cooperate to complete the trial.\n5. Patients with poor compliance","50 Years","80 Years",{"count":21,"type":22},"The study aims to construct an early warning model for Osteoporotic Vertebral Compression Fracture (OVCF) by integrating TCM syndrome patterns with modern risk factors. This is a multi-center cohort study on OVCF integrated with disease and syndrome differentiation in Traditional Chinese Medicine (TCM).",[75,76],"OVCF Database","Cohort Study",[78,79,80,81],"Osteoporotic Vertebral Compression Fractures","Traditional Chinese Medicine","Potential biomarkers","Risk prediction model","2026-01-07",{"date":84,"type":54},"2026-01-09",{"date":86,"type":22},"2026-01-10",{"date":88,"type":22},"2027-12-31",{"name":60,"class":61},{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":18,"minAge":70,"maxAge":97,"enrollmentInfo":98,"targetDuration":4,"studyType":100,"phases":101,"briefSummary":103,"conditions":104,"keywords":106,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":118},"100617662","huangjing-yangji-formula-combined-with-resistance-training-for-sarcopenia-100617662","NCT07321535","Huangjing Yangji Formula Combined With Resistance Training for Sarcopenia","Huangjing Yangji Formula Combined With Resistance Training for Sarcopenia: a Multicenter, Randomized, Double-blind, Placebo-controlled Trial","Inclusion Criteria:\n\n* Meets the diagnostic criteria for sarcopenia according to the Asian Working Group for Sarcopenia (AWGS) 2025 consensus, defined as the co-presence of:\n\nLow Muscle Mass: Appendicular skeletal muscle index (ASMI) measured by multi-frequency bioelectrical impedance analysis (BIA) below the following thresholds:\n\nAges 50-64: \\\u003C7.6 kg\u002Fm² for men, \\\u003C5.7 kg\u002Fm² for women. Ages ≥65: \\\u003C7.0 kg\u002Fm² for men, \\\u003C5.7 kg\u002Fm² for women.\n\nLow Muscle Strength: Handgrip strength below the following thresholds:\n\nAges 50-64: \\\u003C34 kg for men, \\\u003C20 kg for women. Ages ≥65: \\\u003C28 kg for men, \\\u003C18 kg for women.\n\n* Meets the Traditional Chinese Medicine (TCM) pattern diagnosis criteria for Spleen-Kidney Deficiency Syndrome, characterized by:\n\nPrimary Symptoms: Muscle wasting, general fatigue, soreness and weakness of the lower back and knees.\n\nSecondary Symptoms: Poor appetite, abdominal distension, loose or chronic diarrhea, dizziness, poor memory. Tongue presentation: pale and swollen tongue with tooth marks, white and glossy coating. Pulse: deep, thin, and weak.\n\n* Aged between 50 and 75 years.\n* Willing and able to provide written informed consent personally or via a legal guardian.\n\nExclusion Criteria:\n\n* Secondary sarcopenia due to specific diseases (e.g., active malignancy, hyperthyroidism, severe hepatic or renal dysfunction).\n* Presence of severe or uncontrolled cardiovascular disease, consumptive diseases (e.g., cancer), active infections, or severe osteoporosis.\n* Diagnosis of Alzheimer's disease, psychiatric disorders, or other cognitive\u002Fmental impairments that would hinder cooperation with the trial procedures.\n* Inability to perform activities of daily living or walk independently; or presence of motor dysfunction due to joint deformities, prolonged bed rest, fractures, or other reasons that would preclude safe participation in resistance training.\n* Known contraindications to the ingredients of the investigational herbal formula or allergy to the materials of the elastic bands.\n* Use of medications known to affect muscle metabolism (e.g., corticosteroids, muscle relaxants) within the past 3 months.\n* Participation in any other interventional clinical trial within the past 3 months.","75 Years",{"count":99,"type":22},106,"INTERVENTIONAL",[102],"NA","The goal of this clinical trial is to learn if a traditional Chinese medicine formula called \"Huangjing Yangji Formula,\" combined with elastic band resistance training, works better than exercise alone to improve physical function and muscle strength in older adults with sarcopenia (age-related muscle loss). The main questions it aims to answer are:\n\nDoes the combined treatment improve participants' overall physical performance scores more than exercise with a placebo?\n\nDoes it lead to better outcomes in walking speed, balance, muscle strength, body composition, nutrition, mood, sleep, and overall quality of life?\n\nResearchers will compare two groups. One group will take the real Huangjing Yangji Formula granules and do the standardized elastic band resistance training. The other group will take placebo granules (a look-alike mixture with no active medicine) and do the same training.\n\nParticipants will:\n\nTake the assigned granules twice daily for 3 months.\n\nComplete a standardized elastic band exercise program 3 times per week for 3 months (with both group and home sessions).\n\nAttend three assessment visits (at the start, after 3 months, and 1 month after treatment) for tests and questionnaires.\n\nProvide blood samples at the start and after 3 months for routine safety tests and special muscle health markers.",[105],"Sarcopenia",[107,108,109,110],"traditional Chinese medicine","resistance training","randomized controlled trial","multicenter trial","2026-01-05",{"date":82,"type":54},{"date":114,"type":22},"2026-01-15",{"date":116,"type":22},"2026-12-31",{"name":60,"class":61},3,{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":126,"enrollmentInfo":127,"targetDuration":4,"studyType":100,"phases":129,"briefSummary":130,"conditions":131,"keywords":133,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":140,"leadSponsor":142,"locationsCount":4},"100601833","clinical-trial-of-huoluo-pills-combined-with-iguratimod-tablets-in-the-treatment-of-rheumatoid-arthritis-100601833","NCT07115641","Clinical Trial of Huoluo Pills Combined With Iguratimod Tablets in the Treatment of Rheumatoid Arthritis","A Multicenter Clinical Randomized Controlled Trial on the Efficacy and Safety of Huoluo Pills Combined With Iguratimod Tablets in the Treatment of Rheumatoid Arthritis","Inclusion Criteria:\n\n1. Subjects who meet the Western medicine classification criteria for rheumatoid arthritis (RA) launched by the American College of Rheumatology (ACR)\u002FEuropean League Against Rheumatism (EULAR) in 2010 and have been clearly diagnosed with RA.\n2. Subjects who meet the diagnostic criteria for traditional Chinese medicine syndromes of \"Wind-Dampness Obstruction Syndrome (Main symptoms: ① Joint pain and swelling wandering; ② Joint pain and swelling intermittent. Secondary symptoms: ① Aversion to wind or sweating; ② Headache; ③ Heaviness of the limbs. Tongue and pulse manifestations: Pale red tongue thin white coating slippery or floating pulse. Diagnosis can be made by having 2 main symptoms or 1 main symptom + 2 secondary symptoms combined with the tongue and pulse manifestations)\" or \"Cold-Dampness Obstruction Syndrome (Main symptoms: ① Cold joint pain the joints feel cold to the touch and the skin color is not red; ② The pain worsens when exposed to cold and alleviates when warmed. Secondary symptoms: ① Joint stiffness limited flexion and extension; ② Cold limbs or aversion to cold and preference for warmth; ③ Bland taste in the mouth without thirst. Tongue and pulse manifestations: Enlarged tongue body pale tongue white or greasy coating wiry or tight pulse. Diagnosis can be made by having 2 main symptoms or 1 main symptom + 2 secondary symptoms combined with the tongue and pulse manifestations)\".\n3. Subjects with a Disease Activity Score in 28 joints (DAS28) (ESR) score \\> 2.6 and ≤ 5.1 or a DAS28 (CRP) score \\> 2.3 and ≤ 4.1.\n4. Male or female subjects aged ≥ 18 years old and ≤ 70 years old.\n5. Subjects who have not used iguratimod and Huoluo Pills within 4 weeks before the first administration of the investigational drug.\n6. If the subject is receiving treatment with traditional disease-modifying antirheumatic drugs (DMARDs) during screening monotherapy with one of methotrexate (MTX) leflunomide or hydroxychloroquine is allowed and the dosage should be stable for at least 12 weeks before the first administration of the investigational drug (MTX dosage ≤ 15 mg\u002Fweek leflunomide ≤ 20 mg\u002Fday hydroxychloroquine ≤ 400 mg\u002Fday).\n7. Subjects who are receiving treatment with non-steroidal anti-inflammatory drugs (NSAIDs) during screening should have a stable dosage for at least 2 weeks before the first administration of the investigational drug and maintain the same dosage during the trial.\n8. Subjects who are receiving hormone treatment during screening should have a stable condition (limited to oral administration of ≤ 10 mg\u002Fd prednisone acetate or equivalent dose) for at least 4 weeks before the first administration of the investigational drug and maintain stable treatment during the trial.\n9. Subjects who voluntarily agree to participate in this trial sign a written informed consent form are able to follow the visit and related procedures specified in the protocol and have good compliance.\n\nExclusion Criteria:\n\n1. Those who have used plant medicine preparations such as Tripterygium glycosides total glucosides of paeony sinomenine or other traditional Chinese medicine preparations that affect the evaluation of the therapeutic effect within 4 weeks before the first administration of the test drug;\n2. Those who have received intramuscular injection intravenous injection or intra-articular injection of glucocorticoid treatment within 4 weeks before the first administration of the test drug;\n3. Patients who have received treatment with biological agents within 12 weeks before the first administration of the test drug;\n4. Those who suffer from active gastrointestinal diseases (such as peptic ulcers) severe interstitial lung diseases low bone marrow function severe cardiovascular and cerebrovascular diseases (such as acute myocardial infarction unstable angina pectoris intracerebral hemorrhage transient ischemic attack) severe organic lesions such as poorly controlled diabetes mellitus or those who have a history of malignant tumors in the past 5 years or those with mental illnesses. ;\n5. Those known to have tuberculosis HIV hepatitis B hepatitis C syphilis or other active or chronic persistent infections;\n6. Those who are allergic to the drugs involved in the research protocol or have contraindications to their use;\n7. Those who have received live vaccines within 4 weeks before screening or inactivated vaccines within 2 weeks before screening or those who have a vaccination plan during the trial;\n8. Those with any of the following conditions in the auxiliary examination during screening: 1) AST or ALT \\> 1.5 times the upper limit of the normal reference value or the estimated glomerular filtration rate (eGFR) ≤ 60 mL\u002Fmin\u002F1.73m²; 2) Hemoglobin \\\u003C 90 g\u002FL or white blood cell count \\\u003C 3.0×10⁹\u002FL or neutrophil count \\\u003C 1.5×10⁹\u002FL or lymphocyte count \\\u003C 0.5×10⁹\u002FL or platelet count \\\u003C 90×10⁹\u002FL;\n9. Pregnant or lactating women those with a fertility plan or those planning to donate sperm or eggs;\n10. Those who are participating in other clinical trials before screening;\n11. Those whom the investigator deems to have other factors that make them unsuitable to participate in this trial.","70 Years",{"count":128,"type":22},240,[102],"This study aims to systematically evaluate the efficacy and safety of Huoluo Pills combined with Iguratimod Tablets in the treatment of rheumatoid arthritis (RA). A total of 240 patients with RA belonging to the syndromes of Wind - Damp Obstruction or Cold - Damp Obstruction will be enrolled in 8 centers (randomly assigned to groups). The experimental group will receive oral Huoluo Pills combined with Iguratimod Tablets, while the control group will receive oral Iguratimod Tablets alone. Both groups will be administered continuously for 12 weeks.\n\nPrimary Efficacy Index: The proportion of ACR20 responders in each group at the end of treatment.\n\nKey Secondary Efficacy Index: The change in DAS28 (CRP) score from baseline in each group at the end of treatment.\n\nOther Secondary Efficacy Indexes: RF, CRP, ESR, IL - 6, ACR50, ACR70, CDAI, SDAI, HAQ - DI, SF - 36, FACIT - Fatigue, and Traditional Chinese Medicine (TCM) syndrome scores.\n\nSafety Indexes: Physical examination, blood routine, urine routine, blood biochemistry, coagulation function, etc.\n\nThis study will investigate the efficacy and safety of Huoluo Pills combined with Iguratimod Tablets in the treatment of RA with Wind - Damp Obstruction or Cold - Damp Obstruction syndromes.",[132],"Rheumatoid Arthritis",[134,135],"Huoluo Pills","Iguratimod Tablets","2025-08-06",{"date":138,"type":54},"2025-08-11",{"date":138,"type":22},{"date":141,"type":22},"2026-08-31",{"name":60,"class":61},""]